ArticleInternational journal of clinical and experimental pathology2018
Clinicopathological features and prognosis of gastric mixed adenoneuroendocrine carcinoma.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Gastric Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm: An Unusual Tumor and Its Presentation in a Young Adult.GE Portuguese journal of gastroenterology · 2024Article
- Gastric mixed neuroendocrine non-neuroendocrine neoplasms.Frontiers in oncology · 2024Review
- Differences in clinicopathology and prognosis between gastroesophageal junctional and gastric non-cardiac neuroendocrine carcinomas: a retrospective comparison study of consecutive 56 cases from a single institution in China.American journal of cancer research · 2022Article
- Article
- Deficient Mismatch Repair Proteins in Gastric Mixed Neuroendocrine Non-Neuroendocrine Neoplasm: A Rare Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric mixed adenoneuroendocrine carcinomas (MANECs) are rare malignant tumors. This study aimed to investigate the clinicopathological features, diagnosis, prognosis, and treatment outcome in gastric MANECs patients. Clinicopathological data and the archived slides of 40 cases of MANEC patients were retrospectively reviewed. Immunohistochemistry (IHC) staining was performed to detect expression of synaptophysin (Syn), chromogranin A (CgA), CD56, CKpan, CK7, CK8/18, carcinoembryonic antigen (CEA), CK5/6, P40 and Ki-67. Hematoxylin and eosin staining demonstrated exocrine and neuroendocrine components, each accounting for at least 30% of the whole lesion. Exocrine components diffusely expressed epithelial markers CKpan, CK7, CK8/18, and CEA and endocrine components widely expressed at least one of the markers Syn, CgA, and CD56. Ki-67 index and mitosis determined the endocrine component grade as G3. Thirty-three of 40 patients were successfully followed up for 3 to 105 months with median survival of 12 months. Survival analysis showed a significant difference in prognosis with regard to patient's age, disease stage, tumor relapse status, and distant metastasis status. In conclusion, patient's age, disease stage, tumor relapse status, and distant metastasis status are important contributors to poor prognosis. Old patients with advanced stage, recurrence, or metastasis to the liver, pancreas or other distant organs show a poor prognosis.
Indexed as
Identifiers
31938247PMC6958106W3027646193What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.